BioSpace News Archive

Royal Philips, a global leader in health technology, announced the results of its Future Health Index 2024 report: Better care for more people.

Calliditas Therapeutics AB announced that the United States Patent and Trademark Office has issued a patent for application no. 16/760,910 entitled “Use of NOX Inhibitors for Treatment of Cancer.”.

Immunocore Holdings plc (Nasdaq: IMCR) (“Immunocore” or the “Company”) today announces randomization of the first patient in the PRISM-MEL-301 trial, assessing the efficacy and safety of brenetafusp (IMC-F106C; PRAME-A02), in combination with nivolumab, in first-line advanced or metastatic cutaneous melanoma.

Zentalis ® Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration (FDA) has placed a partial clinical hold on the following studies of azenosertib: the Phase 1 ZN-c3-001 dose-escalation study in solid tumors.

Silk Road Medical, Inc. announced it has entered into a definitive agreement to be acquired by Boston Scientific Corporation, a global medical technology leader, for $27.50 in cash per share, representing an equity value of approximately $1.26 billion.

PolyPid Ltd., a late-stage biopharma company aiming to improve surgical outcomes, hosted a virtual Key Opinion Leader event discussing the significant unmet medical need in the prevention of surgical site infections.

Nanoscope Therapeutics Inc. today announced that management will participate in one-on-one meetings with investors at the 2024 Leerink Partners Biopharma Private Company Connect, being held virtually on June 25-26, 2024.

Ascidian Therapeutics today announced a research collaboration and licensing agreement with Roche (SIX: RO, ROG; OTCQX: RHHBY) for the discovery and development of RNA exon editing therapeutics targeting neurological diseases.

REGENXBIO Inc. (Nasdaq: RGNX) today announced it completed a successful Pre-Biologics License Application (BLA) meeting for RGX-121 for the treatment Mucopolysaccharidosis Type II (MPS II), where it finalized details of its BLA with the U.S. Food and Drug Administration (FDA).

Marea Therapeutics today with $190 million in combined Series A and B financings.